



# Analyst Day Meeting

**Scott R. Ward**  
Chairman, President & CEO

July 31, 2018

# Safe Harbor

## FORWARD LOOKING STATEMENTS

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For examples, statements in this presentation regarding CSI's growth, future financial measurements, product introductions, clinical trials, and market opportunities, are forward-looking statements. These statements involve risks and uncertainties that could cause results differ materially from those projected, including, but not limited to, those described in CSI's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly and annual reports. CSI encourages you to consider all of these risks, uncertainties and other factors carefully in evaluating the forward-looking statements contained in this presentation. As a result of these matters, changes in facts, assumptions not being realized or other circumstances, CSI's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this presentation. The forward-looking statements contained in this presentation are made only as of the date of this presentation, and CSI undertakes no obligation to update them to reflect subsequent events or circumstances.

## FINANCIAL INFORMATION

This presentation includes calculations or figures that have been prepared internally and have not been reviewed or audited by CSI's independent registered accounting firm. Use of different methods for preparing, calculating or presenting information may lead to differences, which may be material. In addition, this presentation also includes certain non-GAAP financial measures, such as Adjusted EBITDA. Reconciliations of the non-GAAP financial measures used in this presentation to the most comparable U.S. GAAP measures for the respective periods can be found in tables in the appendix to this presentation. Non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation or as a substitute for CSI's financial results prepared in accordance with GAAP.

# Cardiovascular Systems, Inc.

Creating Shareholder Value

## Leveraging a Strong Core Business

Improving outcomes for complex coronary and peripheral artery disease

Proprietary core technology

Serving large and growing markets

## A Compelling Growth Strategy

Driving market leading performance in orbital atherectomy

Expanding into new geographic markets

Launching an innovative portfolio of new products

## Creating Competitive Advantage

Highest quality products, services and relationships

Innovation and robust medical evidence

Medical education and superior clinical support

## Financially Strong with the Team and Talent to Win

Sustaining double digit growth with strong gross margins

Positive cash flow, strong cash position & no long term debt

Positioned to invest in organic growth

A Mission driven organization with the leadership and talent to succeed

CSI®, Diamondback®, Diamondback 360®, GlideAssist®, ViperWire® and ViperWire Advance® are trademarks of Cardiovascular Systems, Inc.

© 2018 Cardiovascular Systems, Inc.

Sapphire® and OrbusNeich® are trademarks of OrbusNeich Medical, Inc.